Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

APLM

$23.86-4.10%website ↗

Apollomics Inc.

Market Cap
$60M
Sector
Materials
Industry
Biotechnology
Beta
1.35
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
25.6x
buying
Congress
—
recent trades
Short Volume
33%
W/W -26.6pp

Market & Alt Data

News
9
recent articles
Activist
13D
Apollomics
Analyst Consensus
Strong Buy
7 analysts
Velocity Score
25.65x
Current Rate (90d)
6481.49/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
3
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-08-142026-08-17LIN PETER KUAN-HOWChief Financial OfficerPurchase26.7K$15.00$400K49.0KView
2026-08-142026-08-17Chen Hung-WenDirector & Chief Executive OfficerPurchase536.7K$14.07$7.55M1.03MView
2026-08-142026-08-17Chen Yi-KueiDirector & Chief Operating OfficerPurchase20.0K$15.00$300K121.2KView

Recent News

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 2026-08-18
Apollomics Announces $10 Million Private Placement Transaction
Yahoo Finance · 2026-08-11
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Yahoo Finance · 2026-07-13
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Yahoo Finance · 2026-06-24

Informational purposes only, not investment advice.

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Yahoo Finance · 2026-04-27
Apollomics Inc. Announces $2.0 Million Bridge Financing
Yahoo Finance · 2026-04-01
Apollomics Reports First Half 2025 Financial Results
Yahoo Finance · 2025-12-22
Apollomics Announces Settlement of Cayman Litigation
Yahoo Finance · 2025-11-19
Apollomics Announces Changes to its Board of Directors and Composition of Committees
Yahoo Finance · 2025-11-18

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →
Pipeline
Phase 2
2 active trials · readout 2027-01